Calypte Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Alliance with SA Scientific, Inc., will focus on development of a urine-based rapid HIV-1/2 antibody test. Offering results within 15 minutes, the test will be developed and manufactured at SA Scientific's San Antonio facilities; Calypte will manage clinical trials. International distribution is planned for 2002, and the companies are currently focusing efforts to meet FDA's minimum requirements of 98% sensitivity and specificity for a CBER PMA. Once approved, a negative test will eliminate a patient from suspicion, while a positive test will require confirmatory testing with Calypte's FDA-approved HIV-1 urine tests, with results in under three hours...
You may also be interested in...
Calypte Biomedical
Urine-based HIV-1 screening test manufacturer and FDA will discuss accelerating development of a new rapid HIV urine test during a pre-IDE meeting scheduled for early October. Preliminary data indicate 100% sensitivity and specificity, the firm claims. Calypte has an agreement with SA Scientific to develop and manufacture the test at its San Antonio facilities, while Calypte will manage the clinical trials (1"The Gray Sheet" Dec. 3, 2001, In Brief)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.